Partial Matricectomy With Curettage and Electrocautery: A Comparison of Two Surgical Methods in the Treatment of Ingrown Toenails
This study aims to compare 2 surgical methods (partial matricectomy with curettage and electrocautery) in the treatment of ingrown toenails. MATERIALS AND METHODS: A total of 92 ingrown nails of the big toe in 86 patients underwent partial matricectomy with curettage, whereas 57 ingrown nails of the big toe in 52 patients underwent partial matricectomy with electrocautery. RESULTS: Recurrence was observed in 2 toenails in the partial matricectomy with curettage group, whereas no recurrence was observed in the partial matricectomy with electrocautery group (p> .05). The mean period of postoperative pain was 2.3 and 3.1 days in the curettage group and the electrocautery group, respectively (p
ConclusionsWe established the feasibility of initiating and managing patients in a monthly text-based symptom-monitoring program. The provision of smartphones and patient navigation were unique and vital components of this program.
ConclusionsInformatics solutions can generate timely, tailored office reports including PROs and predictive analytics. Patients successfully complete the pre-visit PRO assessments and clinicians and patients value the report to support shared surgical decisions.
ConclusionMultilevel IS frameworks are necessary for PROM/PREM implementation given the complexity. In cross-study comparisons, barriers to PROM/PREM implementation were consistent across patient populations and care settings, but enablers were context specific, suggesting the need for tailored implementation strategies based on clinic resources. Theoretically guided studies are needed to clarify how, why, and in what circumstances IS principles lead to successful PROM/PREM integration and sustainability.
ConclusionThis study was the preparatory phase for a future trial on a method to stimulate setting specific goals. The future trial would provide a thorough understanding of the quality of person-defined goals.
Notice NOT-NS-22-033 from the NIH Guide for Grants and Contracts
Taking inspiration from her PhD research, Ana Moreno formed company where scientists use CRISPR to treat chronic pain
Moderna’s COVID-19 vaccine is safe and efficacious for children ages 6 to 11 years old who recieve two half doses, the company said today. That’s based on the results of its KidCOVE study, which involved more than 4,700 kids in that age group. The children participating in Moderna’s trial were randomly assigned to receive two half doses of the vaccine or two shots of a placebo. Those who got the vaccine generated adequate virus-fighting antibodies that met the U.S. Food and Drug Administration’s (FDA) requirements for efficacy, and the vaccine produced an immune response in nearly all the children. ...
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to...
A recently amended California law will now allow the estates of deceased plaintiffs, including mesothelioma patients, to collect pain and suffering damages. Previously, only the person who sustained bodily injury could recover pain and suffering damages. These damages are often the largest sums of money at stake in many mesothelioma lawsuits. When it becomes law on Jan. 1, Senate Bill 447 will expand the range of recoverable damages and eliminate long-standing restrictions. The amended statute, signed Oct. 1, allows California to join 45 other states that permit the recovery of noneconomic damages for an assort...
Condition: Post Operative Pain, Acute Interventions: Drug: Bupivacaine 0.25% Injectable Solution; Drug: Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg; Drug: Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg, Buprenorphine 300 mcg Sponsor: Wayne State University Recruiting